Cipla receives final approval for generic version of Pfizer’s Depo-Provera

0 31,150

BiznextIndia : Pharma major Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

Cipla’s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer’s Depo-Provera®. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera® and its generic equivalents had US sales of approximately $159M for the 12-month period ending November 2018.

Leave A Reply

Your email address will not be published.